Presidio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Presidio Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7598
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Presidio Pharmaceuticals Inc (Presidio Pharmaceuticals) is a clinical-stage pharmaceutical company that discovers, develops, and supplies small-molecule antiviral therapeutics. The company’s products include HCV NS5A, protease inhibitor, ravidasvir hydrochloride, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, faldaprevir and non-nucleoside inhibitor. Its lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride has completed phase 1 clinical studies in both healthy volunteers and HCV patients. Presidio Pharmaceuticals’ second pan-genotypic HCV inhibitor PPI-383 is a NS5B non-nucleoside inhibitor currently being evaluated in phase 1 studies. The company also has an extensive intellectual property portfolio for its HCV programs. Presidio Pharmaceuticals is headquartered in San Francisco, California, the US.

Presidio Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 11
Presidio Pharma Raises US$8.6 Million In Series D Financing 12
Presidio Pharma Raises Additional US$8 Million In Series C Financing 13
Private Equity 14
Sobera Capital Acquires Equity Holdings in 12 Pharma Companies 14
Licensing Agreements 16
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 16
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 17
Presidio Pharmaceuticals Inc – Key Competitors 18
Presidio Pharmaceuticals Inc – Key Employees 19
Presidio Pharmaceuticals Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 11
Presidio Pharma Raises US$8.6 Million In Series D Financing 12
Presidio Pharma Raises Additional US$8 Million In Series C Financing 13
Sobera Capital Acquires Equity Holdings in 12 Pharma Companies 14
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 16
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 17
Presidio Pharmaceuticals Inc, Key Competitors 18
Presidio Pharmaceuticals Inc, Key Employees 19

List of Figures
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Presidio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kareo Inc:医療機器:M&Aディール及び事業提携情報
    Summary Kareo Inc (Kareo) provides a cloud-based medical technology platform that meets the needs of healthcare providers. The company offers cloud-based electronic health records (EHR) that helps clinicians to manage the care of the patients and record or access required information at the point of …
  • Actelion Ltd:戦略・SWOT・企業財務分析
    Actelion Ltd - Strategy, SWOT and Corporate Finance Report Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Birlasoft Ltd (BSOFT):企業の財務・戦略的SWOT分析
    Birlasoft Ltd (BSOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CareDx Inc (CDNA):医療機器:M&Aディール及び事業提携情報
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • Nippon Shinyaku Co Ltd (4516):製薬・医療:M&Aディール及び事業提携情報
    Summary Nippon Shinyaku Co Ltd (Nippon) is a pharmaceutical company that develops, manufactures and sells ethical pharmaceuticals and functional foods. The company offers a wide range of products including drugs for pain, inflammation, and allergies; urological diseases; hematologic malignancies; ga …
  • Accenture plc:企業のM&A・事業提携・投資動向
    Accenture plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Accenture plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • The Empire District Electric Company:企業の戦略的SWOT分析
    The Empire District Electric Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Intertape Polymer Group Inc (ITP):企業の財務・戦略的SWOT分析
    Intertape Polymer Group Inc (ITP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Biogened SA-製薬・医療分野:企業M&A・提携分析
    Summary BIOGENED SA (Biogened) is a drug company that develops, produces, and distributes Rx medicines and dietary supplements. The company’s products include recipes dermocosmetic products, specialized products, active ingredients, pharmaceutical products, and cosmetic products. Its also offers nov …
  • Rowan Companies plc:企業の戦略・SWOT・財務分析
    Rowan Companies plc - Strategy, SWOT and Corporate Finance Report Summary Rowan Companies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報
    Summary Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which in …
  • Eletrosul Centrais Eletricas SA:電力:M&Aディール及び事業提携情報
    Summary Eletrosul Centrais Eletricas SA (Eletrosul) is a power generation company. The company’s business activities include generation, transmission, commercialization of energy and telecommunication services. It also invests in research and development of alternative energy sources. Eletrosul’s ge …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Sohu.com Inc. (SOHU):企業の財務・戦略的SWOT分析
    Sohu.com Inc. (SOHU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Pebblebrook Hotel Trust:企業の戦略・SWOT・財務情報
    Pebblebrook Hotel Trust - Strategy, SWOT and Corporate Finance Report Summary Pebblebrook Hotel Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • U-Shin Ltd.:企業の戦略的SWOT分析
    U-Shin Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Orange Belgium (OBEL):企業の財務・戦略的SWOT分析
    Orange Belgium (OBEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary NovaDigm Therapeutics Inc (NovaDigm) is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company’s products include NDV-3 vaccines, ALS3 vaccines, vaccine clinical supplies, bacterial and fungal vaccine antigens, vaginal …
  • Fcmb Group Plc:企業の戦略・SWOT・財務分析
    Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report Summary Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆